Compare PEBO & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEBO | ALVO |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2005 | N/A |
| Metric | PEBO | ALVO |
|---|---|---|
| Price | $34.90 | $3.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $37.33 | $8.00 |
| AVG Volume (30 Days) | 144.9K | ★ 378.5K |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $197,000.00 | N/A |
| Revenue This Year | $17.29 | $13.28 |
| Revenue Next Year | $2.97 | $18.63 |
| P/E Ratio | $42.93 | ★ $18.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.49 | $3.03 |
| 52 Week High | $35.46 | $11.85 |
| Indicator | PEBO | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 46.87 |
| Support Level | $33.56 | $3.13 |
| Resistance Level | $35.46 | $3.74 |
| Average True Range (ATR) | 0.60 | 0.17 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 86.27 | 29.91 |
Peoples Bancorp Inc (Marietta OH) is a financial holding company. As a community bank, it offers a complete line of banking, insurance, investment, and trust solutions through its financial subsidiaries. It offers demand deposit accounts, savings accounts, real estate mortgage loans, merchant credit card transaction processing services, corporate and personal trust services, life, health, property, and casualty insurance products, and brokerage services. The bank also offers telephone and internet-based banking through both personal computers and mobile devices.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.